Financial Performance - Q3 2025 revenue reached ¥295,182,271.28, an increase of 5.37% year-over-year, while year-to-date revenue decreased by 1.11% to ¥855,274,926.40[5] - Net profit attributable to shareholders for Q3 2025 was ¥10,070,740.55, a significant increase of 230.99%, with year-to-date net profit rising by 232.18% to ¥54,395,334.20[5] - Basic earnings per share for Q3 2025 was ¥0.0637, reflecting a 230.00% increase, with year-to-date earnings per share at ¥0.3442, also up by 229.38%[5] - Total operating revenue for Q3 2025 was CNY 855,274,926.40, a decrease of 1.8% from CNY 864,900,603.72 in the previous year[32] - Net profit for Q3 2025 reached CNY 53,557,958.28, significantly up from CNY 10,531,607.50 in the same period last year, representing a year-over-year increase of 408.5%[33] - Operating profit for the period was CNY 81,683,638.08, compared to CNY 47,276,046.04 in the previous year, indicating a growth of 72.6%[33] Assets and Liabilities - Total assets as of the end of Q3 2025 amounted to ¥2,254,311,852.20, a 1.30% increase from the end of the previous year[5] - The total assets as of Q3 2025 amounted to CNY 2,254,311,852.20, slightly up from CNY 2,225,440,397.53 in the previous year[32] - Total liabilities decreased to CNY 344,048,178.86 from CNY 345,714,195.13, reflecting a reduction of 0.5%[32] - Total liquid assets decreased from ¥767,321,351.31 to ¥365,237,231.60, a decline of approximately 52.3%[30] - Total current assets increased from ¥1,405,147,188.44 to ¥1,519,747,430.48, an increase of approximately 8.1%[30] - Total non-current assets decreased from ¥1,000,000,000 to ¥1,000,000,000, reflecting stability in long-term investments[30] Cash Flow - The company’s net cash flow from operating activities for the first nine months of 2025 was ¥170,499,922.20, reflecting a 23.63% increase[5] - Operating cash flow for the current period is ¥170,499,922.20, an increase of 23.6% compared to ¥137,910,544.21 in the previous period[34] - Cash flow from investment activities for the first nine months of 2025 was -¥51,739,840, a decrease of 257.21% year-over-year, primarily due to increased purchases of financial products[23] - Total cash inflow from investment activities is ¥2,287,819,378.03, significantly higher than ¥84,076.45 in the previous period[34] - Net cash flow from investment activities is -¥517,398,406.38, worsening from -¥144,846,120.88 in the previous period[34] - Cash and cash equivalents at the end of the period stand at ¥362,158,129.76, down from ¥1,383,595,479.90 in the previous period[35] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,888[25] - Major shareholder 何伟 holds 19.19% of shares, totaling 30,327,379 shares[25] - The company repurchased 2,722,719 shares, accounting for 1.72% of total share capital[26] - 何伟, 何向东, and 付丽芳 signed a concerted action agreement, indicating a unified shareholder strategy[26] - The company has a total of 74,936,340 restricted shares, with 36,392,855 shares released during the period[28] Investment and Expenses - Investment income for the first nine months of 2025 surged to ¥9,739,700, a staggering increase of 1,313,133.75% compared to the previous year, due to adjustments in cash management of idle funds[18] - Research and development expenses for the quarter were CNY 10,475,430.11, down from CNY 13,724,401.11, a decrease of 23.8%[32] - The company’s non-operating income for the first nine months of 2025 increased by 207.31% to ¥470,500, mainly due to an increase in compensation received[21] Accounting and Reporting - The company has not yet audited the third-quarter financial report[36] - The company will implement new accounting standards starting from 2025[36]
何氏眼科(301103) - 2025 Q3 - 季度财报